The Hunt for the Next 10 Bagger

[BioSpecialist]

BXRX =MC $65 M--FDA DECISION next month ..GREAT News out today

BXRX =MC $65 M -Cash $20 M - O/S 9 M / FDA Decision NEXT month for Non-Opioid Pain Drug --Undiscovered low float stockwith brutal upside potential could hit $15 even before FDA Decision

Baudax Bio Announces PDUFA Date for Intravenous Meloxicam
https://finance.yahoo.com/news/baudax-bio-announces-pdufa-date-120010357.html

PDUFA Goal Date Set for February 20, 2020



Baudax’s key product is Anjeso, a long-acting intravenous formulation of meloxicam, an established non-opioid pain reliever, available through an oral formulation. “We see a high probability of FDA approval in the first quarter of 2020, which would be a meaningful catalyst to drive the stock towards our fair value,” writes analyst Ester Hong. She estimates peak U.S. sales of $355-million for Anjeso but sees “upside from increased demand for a potent non-opioid that allows patients to recover and go home faster.”